Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Cocrystal Pharma Inc COCP reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A.

  • The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-ascending doses, plans to enroll 56 healthy adults. 
  • Results from the first two single-ascending dose 100 mg and 200 mg cohorts showed a favorable pharmacokinetic profile of CC-42344. 
  • CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication. 
  • Related: Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19.
  • CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. 
  • In vitro testing showed CC-42344's excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu and Xofluza, while also demonstrating favorable pharmacokinetic and safety profiles.
  • Price Action: COCP shares are up 3.92% at $0.53 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!